<DOC>
	<DOCNO>NCT00003632</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining chemotherapy peripheral stem cell transplantation may allow doctor give high dos chemotherapy drug kill tumor cell . PURPOSE : Phase II trial study effectiveness combination chemotherapy plus peripheral stem cell transplantation treat patient newly diagnose CNS lymphoma .</brief_summary>
	<brief_title>Combination Chemotherapy Plus Peripheral Stem Cell Transplantation Treating Patients With Newly Diagnosed Central Nervous System Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : I. Assess efficacy treatment-related toxicity high-dose chemotherapy comprise carmustine , etoposide , cytarabine , melphalan follow autologous peripheral blood stem cell transplantation patient primary central nervous system lymphoma . II . Determine safety regimen patient . III . Determine efficacy regimen , term 2-year disease-free survival , patient . IV . Assess neurologic outcome use serial neurologic examination patient treat regimen . OUTLINE : Induction therapy : Patients receive methotrexate ( MTX ) IV 2 hour week 1 , 3 , 5 , 7 . Patients respond treatment receive fifth dose MTX week 9 follow cytarabine ( ARA-C ) IV 3 hour begin 3 day completion MTX infusion continue daily 2 day . Filgrastim ( G-CSF ) administer daily begin 2 day completion ARA-C infusion continue harvest peripheral blood stem cell ( PBSC ) . Patients receive second course ARA-C IV begin 1 month completion first course ARA-C continue daily 2 day . G-CSF administered daily 2 week . High-dose chemotherapy/transplantation : Patients stable respond disease induction therapy receive high-dose carmustine IV 1-2 hour day -7 , etoposide IV 1 hour every 12 hour ARA-C IV every 12 hour day -6 -3 , melphalan IV day -2 . PBSC reinfused day 0 . Patients receive G-CSF beginning day 1 continue blood count recover . Patients follow monthly 3 month , every 3 month 9 month , every 4 month 1 year , every 6 month 3 year , annually thereafter . PROJECTED ACCRUAL : A total 15-30 patient accrue study within 3 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Carmustine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm newly diagnose primary central nervous system ( CNS ) lymphoma Patients inconclusive biopsy candidate biopsy may eligible provided typical cranial MRI CT scan ( presence hypo , iso , hyperdense parenchymal contrastenhancing mass lesion ) insure leptomeningeal nonparenchymal lymphoma include Must meet least one follow criterion : Positive CSF cytology lymphoma monoclonal lymphocyte population define cell surface marker Biopsy vitreous uvea demonstrate lymphoma Isolated CNS relapse systemic nonHodgkin 's lymphoma allow PATIENT CHARACTERISTICS : Age : Not specify Performance status : Not specify Life expectancy : At least 8 week Hematopoietic : WBC least 4,000/mm3 Platelet count least 150,000/mm3 Hepatic : Bilirubin great 2.0 mg/dL SGOT great 2 time upper limit normal Renal : Creatinine great 1.5 mg/dL OR Creatinine clearance least 50 mL/min Cardiovascular : Ejection fraction least 50 % Pulmonary : DLCO least 50 % Other : HIV1 negative No active primary malignancy except basal cell skin cancer carcinoma situ cervix No prior immunodeficiency ( e.g. , renal transplantation recipient ) PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy CNS lymphoma Endocrine therapy : Not specify Radiotherapy : No prior cranial irradiation Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>primary central nervous system non-Hodgkin lymphoma</keyword>
</DOC>